New Chemistry Director at Its European Site
New Chemistry Director at Its European Site
Wednesday, November 28, 2007; Posted: 09:38 AM
BUDAPEST, Hungary, Nov 28, 2007 (BUSINESS WIRE) -- (NASDAQ: AMRI) has named Dr. Philip William Small as director of chemistry at its Hungarian site.
In his new position, Dr. Small will assume responsibilities for all of AMRI's European chemistry related activities including custom synthesis, medicinal chemistry, analytical services, library design and production.
He brings over 20 years of practical and managerial experience in medicinal and combinatorial chemistry gained at leading combinatorial chemistry/drug discovery companies. Most recently, Dr. Small was the vice president and head of high-throughput chemistry operations at Tripos Discovery Research in England, where he was in charge of approximately 90 scientists. In this position, he was responsible for influencing the strategic direction, policies and goals/objectives of the company. He played a major role in successfully developing the company from a staff of 12 people up to 170, and was the project manager for the largest project ever overtaken by Tripos Discovery Research (delivering 400,000 compounds worth $100 million over 4 years).
Prior to Tripos, he held chemistry leadership roles with OSI Pharmaceuticals (Birmingham, UK), Oxford Diversity/OAI (Oxford, UK) and Unilever Research (Merseyside, UK). Dr. Small obtained his Ph.D. degree in organic chemistry from the University of Wolverhampton in 1983.
"We are pleased to welcome Dr. Small to our management team at our Hungarian subsidiary," said AMRI CEO Thomas E. D'Ambra, Ph.D. "His valuable experience in leadership and project management will play a vital role in accelerating growth in our European operations," added Dr. D'Ambra.
"Dr. Small's expertise in medicinal and combinatorial chemistry brings additional value to our knowledge base and skills, strengthening our capability to provide innovative, problem-solving chemistry services that best meet our clients' outsourcing needs," said Michael A. Guaciaro, Ph.D., Managing Director of AMRI's Hungarian Operations.
Founded in 1991, AMRI provides scientific services, technologies and products that improve quality of life while delivering excellence, value and maximum return. AMRI's core business consists of a fee-for service contract services platform encompassing drug discovery, development and manufacturing; and a separate, standalone R&D division comprising proprietary technologies, internal drug discovery and bundled capabilities designed for more collaborative relationships. With locations in the U.S., Europe, and Asia, AMRI provides customers with a range of services and cost models.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2005 as filed with the Securities and Exchange Commission on March 16, 2006 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.
Source: http://www.tradingmarkets.com
Wednesday, November 28, 2007; Posted: 09:38 AM
BUDAPEST, Hungary, Nov 28, 2007 (BUSINESS WIRE) -- (NASDAQ: AMRI) has named Dr. Philip William Small as director of chemistry at its Hungarian site.
In his new position, Dr. Small will assume responsibilities for all of AMRI's European chemistry related activities including custom synthesis, medicinal chemistry, analytical services, library design and production.
He brings over 20 years of practical and managerial experience in medicinal and combinatorial chemistry gained at leading combinatorial chemistry/drug discovery companies. Most recently, Dr. Small was the vice president and head of high-throughput chemistry operations at Tripos Discovery Research in England, where he was in charge of approximately 90 scientists. In this position, he was responsible for influencing the strategic direction, policies and goals/objectives of the company. He played a major role in successfully developing the company from a staff of 12 people up to 170, and was the project manager for the largest project ever overtaken by Tripos Discovery Research (delivering 400,000 compounds worth $100 million over 4 years).
Prior to Tripos, he held chemistry leadership roles with OSI Pharmaceuticals (Birmingham, UK), Oxford Diversity/OAI (Oxford, UK) and Unilever Research (Merseyside, UK). Dr. Small obtained his Ph.D. degree in organic chemistry from the University of Wolverhampton in 1983.
"We are pleased to welcome Dr. Small to our management team at our Hungarian subsidiary," said AMRI CEO Thomas E. D'Ambra, Ph.D. "His valuable experience in leadership and project management will play a vital role in accelerating growth in our European operations," added Dr. D'Ambra.
"Dr. Small's expertise in medicinal and combinatorial chemistry brings additional value to our knowledge base and skills, strengthening our capability to provide innovative, problem-solving chemistry services that best meet our clients' outsourcing needs," said Michael A. Guaciaro, Ph.D., Managing Director of AMRI's Hungarian Operations.
Founded in 1991, AMRI provides scientific services, technologies and products that improve quality of life while delivering excellence, value and maximum return. AMRI's core business consists of a fee-for service contract services platform encompassing drug discovery, development and manufacturing; and a separate, standalone R&D division comprising proprietary technologies, internal drug discovery and bundled capabilities designed for more collaborative relationships. With locations in the U.S., Europe, and Asia, AMRI provides customers with a range of services and cost models.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2005 as filed with the Securities and Exchange Commission on March 16, 2006 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.
Source: http://www.tradingmarkets.com
<< Home